The International Journal of Mycobacteriology

: 2022  |  Volume : 11  |  Issue : 3  |  Page : 341--342

Tumor necrotic factor pathway, monkeypox, and tuberculosis: Correspondence

Rujittika Mungmunpuntipantip1, Viroj Wiwanitkit2,  
1 Private Academic Consultant, Bangkok, Thailand
2 Department of Biological Science, Joseph Ayobaalola University, Ikeji-Arakeji, Nigeria; Department of Community Medicine, Dr. D. Y. Patil University, Pune, Maharashtra, India; Department of Medical Science, Faculty of Medicine, University of Nis, Nis, Serbia

Correspondence Address:
Rujittika Mungmunpuntipantip
Private Academic Consultant, 111 Bangkok 112 Bangkok 103300, Bangkok

How to cite this article:
Mungmunpuntipantip R, Wiwanitkit V. Tumor necrotic factor pathway, monkeypox, and tuberculosis: Correspondence.Int J Mycobacteriol 2022;11:341-342

How to cite this URL:
Mungmunpuntipantip R, Wiwanitkit V. Tumor necrotic factor pathway, monkeypox, and tuberculosis: Correspondence. Int J Mycobacteriol [serial online] 2022 [cited 2022 Dec 5 ];11:341-342
Available from:

Full Text

Dear Editor,

In modern clinical medicine, novel zoonotic infections are a major source of worry.[1] A serious public health issue has been created by the spread of monkeypox throughout Europe.[2] A unusual form of the pox called “monkeypox” has likely resurfaced due to zoonosis.[1] A serious public health problem has been created by the spread of monkeypox throughout Europe, America, and Asia.[2] Uncommon monkeypox has returned, most likely as a result of zoonosis. It is being thought about if human-to-human transfer is a possibility. As the number of cases reported in various nations rises, the medical community is alarmed, and meticulous planning is needed to prepare for a potential major outbreak. We must act quickly and decisively to undertake a thorough investigation and put essential counteracting in place.[2] Monkeypox infection is traditionally endemic throughout Western Africa, particularly in Nigeria. Tuberculosis is a major local public health hazard in the same area. However, there has never been a report of coinfection or a contemporaneous outbreak in this location. Using bioinformatic pathophysiological pathway analysis, the authors investigate the pathophysiological pathways of both monkeypox and tuberculosis. The most typical path is being examined. This is the standard technique used in previous pathophysiological pathway analysis research to understand the pathophysiological process of virus infection.[3] Based on pathway analysis, the tumor necrotic factor pathway was found as a common pathway in both disorders. Monkeypox can impair NK cell degranulation and inhibit interferon- and tumor necrosis factor-alpha release via the tumor necrosis factor receptor pathway.[4] Whereas, antitumor necrotic factor alpha is the new current recommended strategy for tuberculosis treatment.[5] [Figure 1] is a schematic of a frequent pathway. The pathophysiological process of monkeypox has a reversible effect on tuberculosis. The new findings imply that tuberculosis and monkeypox share a natural competitive pathophysiological pathway, which could explain the two important local infectious diseases' unusual co-occurrence in endemic African regions.{Figure 1}

Financial support and sponsorship


Conflicts of interest

There are no conflicts of interest.


1Wiwanitkit S, Wiwanitkit V. Atypical zoonotic pox: Acute merging illness that can be easily forgotten. J Acute Dis 2018;7:88-9.
2Mungmunpuntipantip V, Wiwanitkit V. Re-emerging monkeypox: An old disease to be monitored. BMJ Rapid Response Accessible onlineat 22. [Last accessed on 21 May 20].
3Yasri S, Wiwanitkit V. Usefulness of ginseng in management of dengue: A bioinformatics pathway interrelationship analysis. Int J Physiol Pathophysiol Pharmacol 2022;14:114-7.
4Song H, Josleyn N, Janosko K, Skinner J, Reeves RK, Cohen M, et al. Monkeypox virus infection of rhesus macaques induces massive expansion of natural killer cells but suppresses natural killer cell functions. PLoS One 2013;8:e77804.
5Godfrey MS, Friedman LN. Tuberculosis and biologic therapies: Anti-tumor 75 necrosis factor-α and beyond. Clin Chest Med 2019;40:721-39.